Sukyung (Sue) Woo, Ph.D.
Our research utilizes a quantitative systems pharmacology approach that combines computational and experimental methods to guide development of new therapies and potential combination therapies and identification of novel biomarkers for cancer. Quantitative systems pharmacology is integrating systems pharmacology with pharmacokinetics/pharmacodynamics (PK/PD) to advance drug discovery and understanding of drug action, and holds great promise to facilitate translational research. The Translational PK/PD Modeling & Simulation Facility contains advanced computational infrastructure that is capable of performing complex biomedical translational PK/PD analysis. The research is also focused on investigating how genetic polymorphisms in drug metabolizing enzymes and transporters as well as in drug targets (e.g., ligands, receptors) influence disposition, toxicity, and efficacy of targeted anticancer agents and translating these findings toward personalized medicine.
Publications & Presentations
- Jaiprasart P, Devapatla B, Woo S. Identification of molecular signature of resistance to anti-VEGF therapy in ovarian cancer. In Press
- Sharma A, Benbrook D, Woo S. Pharmacokinetics and interspecies scaling of a novel, orally-bioavailable anti-cancer drug, SHetA2. PLOS One. In Press
- Lim S Y, Woo S, Miller J L, Lewis T V, Henry E D, Johnson P N. Dosing for fentanyl infusions in obese children: Just because it’s what we have always done doesn’t mean it’s right. Journal of Pediatric Pharmacology and Therapeutics. In Press
- Jaiprasart P, Yeung B Z, Lu Z, Wientjes M G, Cui M, Hsieh C, Woo S, Au J. Anionic drug reduces intracellular bioavailability and transfection efficiency of cationic siRNA lipoplex. Journal of Controlled Release. 2017; 270 : 101-113
- Ibach B W, Miller J L, Woo S, Harrison D, Standifer K, Hagemann T M, Johnson P N. Characterization of tolerance in children during fentanyl continuous infusions. J Pediatr Intensive Care. 2017; 6 : 83-90